Skip to main content

Catalyst Calendar

Scope

Thu, Sep 10, 2026

1 updates
BLRX
7:00 AM

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small

Presentation / Abstract • Phase 1/2EANO mini-oral presentation Fri, Sep 25, 2026, 6:00 PM CESTbiolinerx.com

Mon, Aug 31, 2026

1 updates
BLRX
7:00 AM

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent antitumor activity in TMZ-resistant patient-derived xenograft (PDX) GBM in vivo model - - Announced

Presentation / Abstract • Phase 1/2ESMO abstract release Thu, Oct 1, 2026biolinerx.com

Fri, Aug 28, 2026

1 updates

Tue, Aug 25, 2026

1 updates
BLRX
7:00 AM

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its

biolinerx.com

Mon, Jul 20, 2026

1 updates